Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma

NCT07677813 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

66

Enrollment

OTHER

Sponsor class

Conditions

DLBCL - Diffuse Large B Cell Lymphoma

Interventions

DRUG: R-CHOP+Orelabrutinib
DRUG: POLA-R-CHP+orelabrutinib
DRUG: R-miniCHOP +orelabrutinib
DRUG: Zuberitamab-CHOP+orelabrutinib
DRUG: POLA-Hi-CHP+orelabrutinib
DRUG: Hi-miniCHOP +orelabrutinib
DRUG: RMTO
DRUG: HiMTO
DRUG: Pola-R-miniCHP+O
DRUG: Pola-Hi-miniCHP

Sponsor

Ou Bai, MD/PHD